ReviewInflammopharmacology2026
Caspase-1 inhibition: mechanistic insights and comprehensive review of reported inhibitors to date.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caspase-1 is a key protease that regulates inflammation by mediating the maturation of pro-inflammatory cytokines IL-1β and IL-18 as well as inducing the pyroptotic cell death. Dysregulation in caspase-1 activity is implicated in various inflammatory, autoimmune and metabolic disorders. This review systematically analyzes natural, synthetic and computationally predicted caspase-1 inhibitors, emphasizing their structural, mechanistic and pharmacological characteristics. We provide data on cellular and enzymatic inhibition, including IC₅₀ values when they are available and list the compounds that have moved on to preclinical or clinical trials. Selective inhibition of caspase-1 remains challenging because the catalytic domain and substrate-binding pocket are highly conserved among caspase family, which makes it challenging to design specific inhibitors. Although, numerous candidates reported exhibit promising caspase-1 inhibitory activities, however, there is still a lack of research regarding caspase-1-specific inhibitors, and further studies are required to investigate novel and effective caspase-1 inhibitors, through in vivo, in vitro, and in silico approaches and their cytotoxicity, bioavailability and solubility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.